- Home
- CRNT vs ACRS Comparison
CRNT vs ACRS Comparison
Compare CRNT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNT
- ACRS
- Stock Information
- Founded
- CRNT 1996
- ACRS 2012
- Country
- CRNT Israel
- ACRS United States
- Employees
- CRNT N/A
- ACRS N/A
- Industry
- CRNT Radio And Television Broadcasting And Communications Equipment
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- CRNT Technology
- ACRS Health Care
- Exchange
- CRNT Nasdaq
- ACRS Nasdaq
- Market Cap
- CRNT 218.8M
- ACRS 198.2M
- IPO Year
- CRNT 2000
- ACRS 2015
- Fundamental
- Price
- CRNT $2.42
- ACRS $1.89
- Analyst Decision
- CRNT Strong Buy
- ACRS Strong Buy
- Analyst Count
- CRNT 4
- ACRS 9
- Target Price
- CRNT $5.50
- ACRS $9.25
- AVG Volume (30 Days)
- CRNT 776.5K
- ACRS 1.1M
- Earning Date
- CRNT 11-12-2025
- ACRS 11-05-2025
- Dividend Yield
- CRNT N/A
- ACRS N/A
- EPS Growth
- CRNT 34.68
- ACRS N/A
- EPS
- CRNT 0.15
- ACRS N/A
- Revenue
- CRNT $380,518,000.00
- ACRS $16,789,000.00
- Revenue This Year
- CRNT N/A
- ACRS N/A
- Revenue Next Year
- CRNT $7.47
- ACRS $7.02
- P/E Ratio
- CRNT $16.20
- ACRS N/A
- Revenue Growth
- CRNT 5.06
- ACRS N/A
- 52 Week Low
- CRNT $1.82
- ACRS $1.05
- 52 Week High
- CRNT $5.73
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- CRNT 59.11
- ACRS 48.51
- Support Level
- CRNT $2.25
- ACRS $1.81
- Resistance Level
- CRNT $2.49
- ACRS $1.94
- Average True Range (ATR)
- CRNT 0.10
- ACRS 0.09
- MACD
- CRNT 0.00
- ACRS -0.01
- Stochastic Oscillator
- CRNT 54.47
- ACRS 27.51
About CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.